Revance Therapeutics Inc (RVNC) Gross Profit Margin starting from the third quarter 2024 to third quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Revance Therapeutics Inc   (NASDAQ: RVNC)


Revance Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RVNC Gross Profit Margin (Sep 30 2024)
Q3 		(Jun 30 2024)
Q2 		(Mar 31 2024)
Q1 		(Dec 31 2023)
Q4 		(Sep 30 2023)
Q3
Y / Y Revenue Change 5.47 %
Seq. Revenue Change -8.43 %
Revenue In Millions $59.88
Gross Profit Margin 70.55 %
Gross Profit Margin Total Ranking # 1037
Gross Profit In Millions $42.25
Y / Y Gross Profit Change 5.73 %
Seq. Gross Profit Change -11.53 %


Commenting Third Quarter 2024 Gross Profit Margin
Revance Therapeutics Inc experienced contraction in Gross Profit by -11.53 % to $60 millions and Revenue by -8.43 %, while Gross Profit Margin fell to 70.55 %, above company*s average Gross Profit Margin.


Observing third quarter 2024 results within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 950 to 1037.
Learn about Gross Margin
RVNC's Gross Profit Margin third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 91
Healthcare Sector # 181
Overall # 1026

Gross Profit Margin Statistics
High Average Low
85.33 % 56.03 % 4.93 %
(Mar 31 2015)   (Sep 30 2020)


RVNC Gross Income Trends • More of RVNC's Profitabilty Ratios • RVNC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
RVNC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
RVNC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for RVNC's Competitors
Gross Profit Margin Profit Margin for Revance Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for RVNC's Customers

You may also want to know
RVNC's Annual Growth Rates RVNC's Profitability Ratios RVNC's Asset Turnover Ratio RVNC's Dividend Growth
RVNC's Roe RVNC's Valuation Ratios RVNC's Financial Strength Ratios RVNC's Gross Profit Growth
RVNC's Roa RVNC's Inventory Turnover Ratio RVNC's Growth Rates RVNC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2024 MRQ Gross ProfitSep 30 2024 MRQ Revenue
Abvc Biopharma Inc   99.92 %$ 0.389  Millions$ 0.389  Millions
Macrogenics Inc   99.85 %$ 110.540  Millions$ 110.708  Millions
Zai Lab Limited  99.66 %$ 101.917  Millions$ 102.265  Millions
Therapeuticsmd Inc   99.45 %$ 0.544  Millions$ 0.547  Millions
Ionis Pharmaceuticals Inc   99.20 %$ 132.743  Millions$ 133.814  Millions
Blueprint Medicines Corporation  98.49 %$ 126.252  Millions$ 128.184  Millions
Corcept Therapeutics Inc  98.43 %$ 179.679  Millions$ 182.546  Millions
Travere Therapeutics Inc   97.41 %$ 61.272  Millions$ 62.898  Millions
Karyopharm Therapeutics Inc   96.65 %$ 37.483  Millions$ 38.783  Millions
Gyre Therapeutics Inc   96.24 %$ 24.530  Millions$ 25.488  Millions
Lexicon Pharmaceuticals Inc   95.94 %$ 1.679  Millions$ 1.750  Millions
Vanda Pharmaceuticals Inc   94.65 %$ 45.100  Millions$ 47.651  Millions
Cormedix Inc   94.01 %$ 10.770  Millions$ 11.456  Millions
Regeneron Pharmaceuticals Inc   92.95 %$ 3,458.400  Millions$ 3,720.700  Millions
Emmaus Life Sciences Inc   92.81 %$ 5.084  Millions$ 5.478  Millions
Acadia Pharmaceuticals Inc   92.47 %$ 231.544  Millions$ 250.401  Millions
Urogen Pharma Ltd   91.92 %$ 22.751  Millions$ 24.751  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Marinus Pharmaceuticals Inc   91.64 %$ 7.827  Millions$ 8.541  Millions
Agios Pharmaceuticals Inc   91.27 %$ 8.181  Millions$ 8.964  Millions
Aurinia Pharmaceuticals Inc   91.10 %$ 61.736  Millions$ 67.771  Millions
Kaya Holdings Inc   90.93 %$ 0.003  Millions$ 0.003  Millions
Polomar Health Services, Inc.  90.82 %$ 0.009  Millions$ 0.010  Millions
Amicus Therapeutics inc   90.80 %$ 128.238  Millions$ 141.238  Millions
Innoviva Inc   90.61 %$ 96.454  Millions$ 106.444  Millions
Supernus Pharmaceuticals inc   89.99 %$ 158.106  Millions$ 175.689  Millions
Optinose Inc   89.90 %$ 18.372  Millions$ 20.437  Millions
Ocular Therapeutix Inc   89.88 %$ 13.864  Millions$ 15.425  Millions
United Therapeutics Corporation  88.90 %$ 665.800  Millions$ 748.900  Millions
Tg Therapeutics Inc   88.86 %$ 74.538  Millions$ 83.879  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.